Mucosal viral infections: achievements and problems


Cite item

Full Text

Abstract

Data obtained in the recent years on developing the viral inactivated mucosal vaccines by applying the mucosaladhesive adjuvants are presented in the survey. Progress achieved in designing the mucosal influenza vaccines and mucosal vaccines againsta variety of other viral infections is pointed out. Cross-protection against variations of a virus within its subtype limits as well as overcoming of a negative influence of parent antibodies produced ort the immunogenicity of live-vaccines', which were used at young age, were observed in the intranasal administration of viral mucosal vaccines. A number of shortcomings of bacterial toxins used as mucosal-adhesive adjuvants as well as problems, which may arise when the viral mucosal vaccines are used on a large-scale basis due to a need in their two- and-threefold intranasal administration, are in the focus of attention.

References

  1. Гендон Ю. 3. Вирусные мукозальные вакцины // Вопр. вирусол. - 1999. - № 3. - С. 100-105.
  2. Гендон Ю. 3. Разработка мукозальных гриппозных инактивированных вакцин // Журн. микробиол. - 2003. - № 3. - С. 98-103.
  3. Alexandrova G., Potezhaev F., Budilovsky G. et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vacinees // Infect. and Immun. - 1984. - Vol. 44. - P. 734-739.
  4. Azakura Y., Landhalm P., Kiersslrom A. et al. DNA-plasmids of HIV-1 induce systemic and mycosal immune responses // J. Biol. Chem. - 1999. - Vol. 380. - P. 375-379.
  5. Belshe R., Mendelman P., Treanor M. et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children // N. Engl. J. Med. - 1998. - Vol. 338. - P. 1405-1412.
  6. Bergsquist C., Johansson E., Lagergard T. et al. Intranasal vaccination of humans with recombinant cholera toxin В subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina // Infect. and Immun. - 1997. - Vol. 65. - P. 2676-2684.
  7. Beyer W., Palache A., de Jong J. et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A metaanalysis // Vaccine. - 2002. - Vol. 20. - P. 1340-1353.
  8. Bruhl P., Kerschbaum A., Eibl M. et al. An experimental primeboost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice // AIDS Res. Hum. Retrovirus. - 1998. - Vol. 14. - P. 401-407.
  9. Bryant M., Brown P., Gurvich N. et al. Comparison of the clearance of radiolabeled nose drops and nasal spray as mucally delivered vaccine // Nucl. Med. Commun. - 1999. - Vol. 20. - P. 171-174.
  10. Cheng E., Cardenas-Freytag L., Clements J. The role of cAMP in mucosal adjuvanticity of E. coli heat-labile enterotoxin (LT) // Vaccine. - 2000. - Vol. 18. - P. 38-49.
  11. Coste A., Sirard J., Johansen K. et al. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea // J. Virol. - 2000. - Vol. 74. - P. 8966-8971.
  12. Couch R., Quarks J., Cate T. et al. Clinical trials with live coldreassortant influenza vaccines // Options for the Control of Influenza. - New York, 1986. - P. 223-241.
  13. Davis S., Ilium L., Gill J. et al. Polymer lamellar particles as a novel adjuvant for influenza vaccines // Options for the Control of Influenza IV. - Crete, Hersonossis, 2000. - Abstr. W62-1. - P. 50.
  14. De Haan L., Willem R., Noltrop M. et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the В subunit of E. coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity // Vaccine. - 2001. - Vol. 19. - P. 2898-2907.
  15. Del Guidece G., Rappuoli R. Genetically derived toxoids for use as vaccines and adjuvants // Ibid. - 1999. - Vol. 17. - P. 44-52.
  16. Dupuy C., Bizoni-Gatel D., Touze A. et al. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 LI gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes // J. Virol. - 1999. - Vol. 73. - P. 9063-9071.
  17. Ferco В., Katinger D., Grassauer A. et al. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract // J. Infect. Dis. - 1998. - Vol 178. - P. 1359-1368.
  18. Gerber S., Lane C., Brown D. et al. Human papillomavirus viruslike particles are efficient oral immunogens when coadministered with E. coli heat-labile enterotoxin mutant R192G or CpG DNA // J. Virol. - 2001. - Vol. 75. - P. 4752-4760.
  19. Gliick U., Gebbers J., Gliick R. Phase I evaluation of intranasal virosomal influenza vaccine with and without E. coli heat-labile toxin in adult volunteers // Ibid. - 1999. - Vol. 73. - P. 7780-7786.
  20. Goetsch L., Gonzales A., Plotnicky H. et al. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae // Infect. and Immun. - 2001. - Vol. 69. - P. 6434-6444.
  21. Goetsch L., Plotnicky H., Aubry J. et al. BBG 2Na an RSV subunit vaccine candidate intramuscularly injection to human confers protection against vital challenge after nasal immunization in mice // Vaccine. - 2001. - Vol. 19. - P. 4036-4042.
  22. Hashigucci K., Ogawa H., Ishidate T. et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with E. coli heat-labile enterotoxin В subunit containing a trace amount of holotoxiik // Ibid. - 1996. - Vol. 14. - P. 113-119.
  23. Huang Y., Anderson R. Enhanced immune protection by a lyposome-encapsulated recombinant RSV vaccine using immunogenic lipms from Deinococcus radiodurans // Ibid. - 2002. - Vol. 20/- P. 1586-1592.
  24. Illum L., Jabal-Gill I., Lin W. et al. The immune response of nasally administered influenza vaccine is enhanced by the polysaccharide chitosan // Options for the Control of Influenza IV. - Crete, Hersonossis, 2000. - Abstr. W62-3. - P. 50.
  25. Illum L., Jabbal-Gill I., Hincheliffe M. et al. Chitozan as novel nasal delivery system for vaccines // Adv. Drug Delivery Rev. - 2001. - Vol. 51. - P. 81-96.
  26. Johnson P., Feldman S., Thompson J. et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine // J. Infect. Dis. - 1986. - Vol. 154. - P. 121-127.
  27. Kang D., Kim P., Ко E. et al. Peroral immunization of microcapsulated human VP8 in combination with cholera toxin induces intestinal antibody responses // Mol. Cells. - 1999. - Vol. 9. - P. 609-616.
  28. Kawana K., Kawana Y., Yoshikawa H. et al. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies // Vaccine. - 2000. - Vol. 19. - P. 1496-1502.
  29. Komase K., Tamura S., Matsuo К. et al. Mutants of E. coli heatlabile enterotoxin as an adjuvant for nasal influenza vaccine // Ibid. - 1998. - Vol. 16. - P. 348-254.
  30. Kozlowski P., Cu-Uvin S., Neutra M. et al. Comparison of the oral rectal and vaginal immunization routes for induction of antibodies in rectal and genital tract secretion of women // Infect. and Immun. - 1997. - Vol. 65. - P. 1387-1394.
  31. Kozlowski P., Cu-Uvin S., Neutra M. et al. Mucosal vaccination strategies for women // J. Infect. Dis. - 1999. - Vol. 179. - Suppl. 3. - P. S493-S498.
  32. Lambert J., Keefer M., Milligan M. et al. A phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects // Vaccine. - 2001. - Vol. 19. - P. 3033-3042.
  33. Liashenko V., Krasnova V., Youminova N. Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measled vaccine L-16 // Hum. Antibodies. - 1999. - Vol. 9. - P. 143-148.
  34. MacDonald M., Li X., Stenberg R. et al. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus infection by using an attenuated mutant // J. Virol. - 1998. - Vol. 72. - P. 442-451.
  35. Mutwiri G., Bateman C., Baca-Estrada M. et al. Induction of immune responses in newborn lambs following enteric immunization with a human adenovirus vaccine vector // Vaccine. - 2000. - Vol. 19. - P. 1284-1293.
  36. Nardelli-Haefinger D., Roden R., Balmelli C. et al. Mucosal but not parenteral immunization with purified human papilomavirus type 16 virus-like particles induces neutralising titers of antibodies throughout the esterous cycle of mice // J. Virol. - 1999. - Vol. 73. - P. 9609-9613.
  37. Niewiesk S. Studing experimental measles virus vaccines in the presence of maternal antibodies in the cotton rat model (Sigmodon hispidus) // Vaccine. - 2001. - Vol. 19. - P. 22502253.
  38. Oien N., Brideau R., Walsh E. et al. Induction of local and systemic immunity against human respiratory syncitial virus using a chimeric FG glycoprotein and cholera toxin В subunit // Ibid. - 1994. - Vol. 12. - P. 731-735.
  39. O'Neal C., Clements J., Estes M. et al. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, E. coli heat-labile toxin (LT), and LT-R1926 induce protection from rotavirus challenge // J. Virol. - 1998. - Vol. 72. - P. 33903393.
  40. Plante M., Jones D., Allard F. et al. Nasal proteosome subunit flu vaccine elicits enhance mucosal IgA, serum HAI and protection comparable to conventional injectable flu vaccine // Options for the Control of Influenza IV / Eds A. Osterhaus et al. - Amsterdam, 2001. - P. 979-984.
  41. Plante M., Jones D., Allard F. et al. Nasal immunization with subunit proteosome influenza vaccine induces serum HAI, mucosal IgA and protection against influenza challenge // Vaccine. - 2002. - Vol. 20. - P. 218-225.
  42. Rapp Z., Middleton D., Mittal S. et al. Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection // J. Gen. Virol. - 1997. - Vol. 78. - P. 2933-2943.
  43. Rapp Z, Babik L., Baca-Estrada M. The effect of pre-existing adenovirus-specific immunity on immune response induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1 // Vaccine. - 1999. - Vol. 17. - P. 933-943.
  44. Rudenko L., Slepushkin A., Monto A. et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia // J. Infect. Dis. - 1993. - Vol. 168. - P. 881-887.
  45. Sanz-Parra A., Vazquez В., Sobrino F. et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (PI) of foot-and-mouth disease virus capsid proteins // J. Gen. Virol. - 1999. - Vol. 80. - P. 671-679.
  46. Sazaki S., Sumino K., Hamajima K. et al. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes // J. Virol. - 1998. - Vol. 72. - P. 4931-4939.
  47. Schmidt A., McAuliffe J., Murphy B. et al. Recombinant bovine/ human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3 // Ibid. - 2001. - Vol. 75. - P. 4594-4603.
  48. Siadat-Pajouh M., Cai L. Protective efficacy of rotavirus 2/6virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant // Viral Immunol. - 2001. - Vol. 14. - P. 31-47.
  49. Stokes C., Finerty S., Graffydd-Jones T. et al. Mucosal infection and vaccination against feline immunodeficiency virus // J. Biotechnol. - 1999. - Vol. 73. - P. 213-221.
  50. Tang S., van Rij R., Silvera D. et al. Towards a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity // J. Virol. - 1997. - Vol. 71. - P. 7841-7850.
  51. Tebbey P., Unczur C., LaPierre N. et al. A novel and effective intrfanasal immunization strategy for respiratory syncytial virus // Viral Immunol. - 1999. - Vol. 12. - P. 41-45.
  52. Velin D., Hopkins S., Krachenbuhl J. Delivery systems and adjuvants for vaccination against HIV // Pathobiology. - 1998. -Vol.66. -P. 170-175.
  53. Welter J., Taylor J., Tartaglia J. et al. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines // J. Virol. - 2000. - Vol. 74. - P. 6358-6367.
  54. Yuan L., Geyer A., Hodgins D. et al. Intranasal administration of 2/6-rotavirus-like particles with mutant E. coli heat-labile toxin (LT-R192G) induces antibody-secreting cell response but not protective immunity in gnotobiotic pigs // Ibid. - 2000. - Vol. 74. - P. 8843-8853.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Gendon Y.Z.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies